GALNT16

Across TCGA pan-cancer cohorts, GALNT16 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GALNT16’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GALNT16 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GALNT16 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where GALNT16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GALNT16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.478	.006	8	view →
LSCC	Male	II,III,IV	−0.798	<.001	7	view →
CCRCC	All	All	−0.542	<.001	7	view →
PDAC	All	III,IV	−1.044	.003	6	view →
LUAD	All	II,III,IV	−0.440	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GALNT16–HNSC

Open the HNSC breakdown →